Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-80
SponsorInstituto Nacional de Cancerologia de Mexico

About this trial

This is a study that aims to demonstrate the non-inferiority of minimally invasive surgery versus open surgery, as an approach for patients with advanced ovarian cancer who received neoadjuvant chemotherapy, giving them the benefits of laparoscopic surgery. This way they can continue with their complementary treatment.

Eligibility criteria

Qualifiers

Diagnosis of epithelial ovarian cancer (all subtypes of epithelial ovarian cancer) in stage III-IV

Partial and complete response to treatment with QTNA after 3-4 cycles, evaluated by PET-CT imaging study, patients that the functional unit decides to incorporate into the project.

Ca 125 which will have to be less than 200

ECOG 0 to 2 without medical contraindication to perform surgery (≤ ASA 2 or ≤ Goldman 2).

Disqualifiers

Partial response with persistence of ascites or pleural effusion.

With unresectability criteria (multiple intrahepatic liver metastases, retroperitoneal lymph node conglomerates >2cm above the renal lymph nodes, metastatic disease above the diaphragm, multiple intestinal involvement and mesentery retraction).

Trial design

Treatments tested in this trial

  • Interval Cytoreduction Surgery

Treatment groups

33 Participants
are divided into 1 treatment group

Sponsors and collaborators

Instituto Nacional de Cancerologia de Mexico

Lead sponsor

None in Three Research Centre

Sponsor institution